Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

thuasne pacific pty ltd - 40508 - shoe, - a shoe or pair of shoes which is intended to be used by a patient/person and which has one or more special features. it may be, e.g. conductive, protective. for corrective footwear, see also: orthosis, footwear, orthopaedic, shoe

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 10668 - shoe, cast - shoe worn over cast to protect the cast material and provide support.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pacific dental specialties pty ltd - 44901 - torque wrench, manual, dental - this is a hand held manual device with an appropriate torque dental and/or retaining screws fitted into the oral cavity during dental surgical procedures.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: gelatin indigo carmine iron oxide red magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg;   - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - capsule - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: gelatin indigo carmine iron oxide black magnesium stearate mannitol microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - modified release capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: calcium hydrogen phosphate dihydrate gelatin hydrogenated vegetable oil hypromellose indigo carmine iron oxide yellow magnesium stearate mannitol povidone purified talc titanium dioxide - madopar hbs is indicated for patients presenting with all types of fluctuation in response, especially those related to fluctuations in plasma levels (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - tetrabenazine 25mg - tablet - 25 mg - active: tetrabenazine 25mg excipient: iron oxide yellow lactose monohydrate magnesium stearate pregelatinised maize starch purified talc - tetrabenazine is indicated for the treatment of moderate to severe tardive dyskinesia, which is disabling and/or socially embarrassing. the condition should be persistent despite withdrawal of antipsychotic therapy, or in cases where withdrawal of antipsychotic medication is not a realistic option; also where the condition persists despite reduction in dosage of antipsychotic medication or switching to atypical antipsychotic medication.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - tetrabenazine 25mg;  ;   - tablet - 25 mg - active: tetrabenazine 25mg     excipient: iron oxide yellow lactose monohydrate magnesium stearate purified talc starch - movement disorders associated with organic central nervous system conditions, e.g. huntington's chorea, hemiballismus and senile chorea. tetrabenazine is also indicated for the treatment of moderate to severe tardive dyskinesia, which is disabling and/or socially embarrassing. the condition should be persistent despite withdrawal of antipsychotic therapy, or in cases where withdrawal of antipsychotic medication is not a realistic option; also where the condition persists despite reduction in dosage of antipsychotic medication or switching to atypical antipsychotic medication.